Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Retained Earnings (2016 - 2025)

Spero Therapeutics' Retained Earnings history spans 10 years, with the latest figure at -$451.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 1.86% year-over-year to -$451.1 million; the TTM value through Dec 2025 reached -$451.1 million, up 1.86%, while the annual FY2025 figure was -$451.1 million, 1.86% up from the prior year.
  • Retained Earnings reached -$451.1 million in Q4 2025 per SPRO's latest filing, up from -$482.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2000.0 in Q2 2021 to a low of -$482.6 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$357.2 million, with a median of -$427.1 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.0% in 2021, then crashed 22029900.0% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$367.5 million in 2021, then decreased by 19.9% to -$440.6 million in 2022, then increased by 11.24% to -$391.1 million in 2023, then fell by 17.53% to -$459.6 million in 2024, then rose by 1.86% to -$451.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Retained Earnings are -$451.1 million (Q4 2025), -$482.6 million (Q3 2025), and -$475.2 million (Q2 2025).